Efgartigimod clinical trials

Explore recruiting efgartigimod clinical trials.

Recruiting efgartigimod studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Efgartigimod trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

Czechia, Italy, Spain, Hungary, Slovakia, Bulgaria +8 more

Phase II and Phase III (Integrated) EU CTIS Study details

ARGX-113-1803: A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia

Italy, Czechia, Poland, Hungary

Therapeutic confirmatory (Phase III) EU CTIS Study details

Open-label Extension of the ARGX-113-1802 Trial to Investigate the Longterm Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Austria, Netherlands, Italy, Belgium, France, Romania +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

Italy, Romania, Greece, Bulgaria, Portugal, Norway

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod IV in Adult Participants With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

Norway, Portugal, Denmark, Germany, Cyprus, Finland +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease

Estonia, Czechia, Germany, Spain, Greece, Hungary +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efgartigimod trials by city

Efgartigimod in Toronto Efgartigimod in Vancouver Efgartigimod in Montreal Efgartigimod in Calgary Efgartigimod in Edmonton Efgartigimod in Ottawa Efgartigimod in Winnipeg Efgartigimod in Quebec City Efgartigimod in Hamilton Efgartigimod in Kitchener Efgartigimod in London Efgartigimod in Halifax Efgartigimod in New York Efgartigimod in Los Angeles Efgartigimod in Chicago Efgartigimod in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease